Delving into the Latest Updates on Elemene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Dalianhualijingang Pharmaceutical Co. Ltd.

Active Organization

Dalianhualijingang Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1996),

Neoplasms

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC15H24

InChIKeyOPFTUNCRGUEPRZ-QLFBSQMISA-N

CAS Registry515-13-9

The goal of this phase II randomized clinical trial is to compare the safety and efficacy of Elemene plus Stupp Protocol (the new protocol) and Stupp Protocol alone (the standard protocol) in patients with newly-diagnosed glioblastomas (ndGBMs). The main questions to answer are:
Whether the new treatment protocol (Elemene plus Stupp Protocol) is clinically safe for ndGBM patients.
Whether the new treatment protocol (Elemene plus Stupp Protocol) brings better survival benefits for ndGBM patients compared to the standard-of-care Stupp Protocol.
Study participants will be enrolled in 5 hospitals in China and randomly assigned to receive either the new protocol or the standard protocol. The overall survival (OS) rate in the 12th month, the progression-free survival (PFS) rate in the 6th month, OS, PFS, and adverse events assessed by the CTCAE (Common Terminology Criteria for Adverse Events) will be evaluated for all patients.

Start Date01 May 2023

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT04674527

/ Unknown statusPhase 2IIT

A Pilot Study of Elemene Injectable Emulsion in Treating Patients With Refractory Glioblastoma

This is a pilot phase I study to evaluate the safety and efficacy on elemene injectable emulsion in treating patients with glioblastoma. Elemene, isolated from the Chinese medicinal herb Curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo.Elemene injectable emulsion against malignant tumors was low. Therefore, the effect of Elemene injectable emulsion being used in clinical settings needs to be confirmed by further RCTs.

Start Date01 Jun 2021

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+1]

ChiCTR2000037148

/ RecruitingNot ApplicableIIT

Clinical study of HIPEC combined with traditional Chinese medicine elemene in the treatment of advanced colorectal cancer

Start Date01 Sep 2020

Sponsor / Collaborator-

100 Clinical Results associated with Elemene

Login to view more data

100 Translational Medicine associated with Elemene

Login to view more data

100 Patents (Medical) associated with Elemene

Login to view more data

10,833

Literatures (Medical) associated with Elemene

01 May 2025·Food Chemistry

Long-term study of Citrus changshan-huyou Y.B. Chang essential oil: Chemical transformations and their impact on antibacterial efficacy

Article

Author: Xiao, Wenbin ; Liu, Ting ; Guo, Jiajing ; Li, Gaoyang ; He, Mingwang ; Fu, Fuhua ; Li, Zixuan ; Shang, Xuebo ; Fu, Yanjiao ; Gao, Zhipeng ; Xiao, Yangbo ; Su, Donglin ; Shan, Yang ; Zhang, Tongping

The essential oil from Citrus changshan-huyou Y.B. Chang (HYEO) contains volatile compounds with strong inhibitory effects on biofilms formed on food processing equipment. This study analyzed the compositional changes of HYEO over 9 years and evaluated its antibacterial and antibiofilm properties. HYEO showed significant antibacterial activity during the first 8 years, effectively removing mature biofilms. Gas chromatography-mass spectrometry analysis revealed that monoterpenes were the primary components, with d-limonene and γ-terpenes converting into oxygenated derivatives during storage, resulting in a more than 16-fold increase in antibacterial activity. The antibacterial strength correlated with the number of oxygenated derivatives from limonene and terpinene among the top 20 components. Significant associations were observed between antibacterial activity and the oxygenated derivatives of d-limonene and γ-terpenes. These findings suggest the need for further investigation into their synergistic effects, antibacterial mechanisms, potential applications in food processing, and the safety profiles of the main antibacterial components of HYEO.

01 Mar 2025·Flavour and Fragrance Journal

Silver Nanoparticles (AgNPs) Act as Nanoelicitors in Melissa officinalis to Enhance the Production of Some Important Phenolic Compounds and Essential Oils

Author: Kapdan, Goncagul ; Coskun, Yasemin

ABSTRACTNanoparticles (NPs) are well‐known biostimulants in plant biotechnology, utilised to enhance the physical properties of plants and exhibit positive effects on them. The important key role is the most suitable type, effective dose and size of NP to be used in plant tissue culture systems. In this study, various concentrations of silver nanoparticles (AgNPs; 0, 25, 50, 75 and 100 μg L−1) were tested as elicitors in callus culture with the aim of enhancing secondary metabolite production in lemon balm (Melissa officinalis L.). According to the results obtained, callus formation rates have shown an increase in all applications compared to the control group. The highest callus formation, weight and diameter were observed in 50 μg L−1 application. In this application, the callus structure was compact and its colour was green. However, the aromatic compounds, neral and geranial increased significantly in 25 μg L−1 application. The maximum increase in phenolic compounds such as caffeic acid, chlorogenic acid, proto‐catechic acid, hesperidin and p‐coumaric acid was observed in the 75 μg L−1 AgNP and the highest increase in rosmarinic acid compound was determined in the 50 μg L−1 application. The study found that AgNP applications are an effective method for increasing the production of secondary metabolites in medicinal and aromatic plants, such as lemon balm, in vitro.

01 Mar 2025·Chemistry & Biodiversity

Chemical Constituents, Antioxidant, and Enzyme Inhibitory Potentials Supported by In‐Silico Studies of the n‐Hexane Extract and Essential Oil of Platycladus Orientalis (L.) Franco Leaves

Article

Author: Korany, Doaa A. ; Eldahshan, Omayma A. ; Nilofar, Nilofar ; Zengin, Gokhan

AbstractPlatycladus orientalis leaves are widely used in traditional medicine to treat different ailments. In the present study, the volatile constituents were obtained by n‐hexane extraction and hydrodistillation. Comprehensive metabolomic profiling was performed using GC‐MS analysis. Furthermore, in vitro antioxidant potential and enzyme‐inhibitory activity were assessed and supported by in silico profiling. Results revealed the predominance of monoterpene hydrocarbons in the hydrodistilled volatile oil (42.30 %) followed by oxygenated sesquiterpenes (32.10 %); with cedrol as the main component. Diterpenoids (49.70 %) and sesquiterpene hydrocarbons (13.43 %) were the major components of the n‐hexane extract; with vulgarol A, a diterpene alcohol, as the major constituent. The volatile oil demonstrated significantly higher antioxidant potential across all assays, including ABTS and DDPH scavenging activity, CUPRAC, and FRAP assays. However, the n‐hexane extract demonstrated broad inhibitory effects against butyrylcholinesterase, tyrosinase, α‐amylase, and α‐glucosidase enzymes, supported by molecular docking study and predictive ADME profiling. Therefore, it may be concluded that the n‐hexane extract is a viable option for treating dysregulated enzyme conditions. In addition, the potential use of volatile oil in the pharmaceutical industries and management of oxidative stress can be inferred. These results warrant further studies to validate the therapeutic potential of the volatile oil and the n‐hexane extract.

100 Deals associated with Elemene

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Elemene	L01XX	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	China	Dalianhualijingang Pharmaceutical Co. Ltd.	01 Jan 1996

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CSCO2022	Not Applicable	Malignant ascites	42	榄香烯乳状注射液	xwcxzrlbiy(lgbnpirxiq) = eqofbyysla mwwtmtpsng (gflfhvvtfx )	Positive	21 Sep 2022
CSCO2021	Not Applicable	Esophageal Carcinoma	50	榄香烯 (单放组)	wdloucnhzv(tmcrnphyhx) = urnvvhbidy mrbvouqyfd (uilzqsqkyq ) View more	-	25 Sep 2021
				榄香烯 (综合组)	wdloucnhzv(tmcrnphyhx) = eiibwqutrf mrbvouqyfd (uilzqsqkyq ) View more
CSCO2021	Not Applicable	HER2 negative Gastric Cancer	66	榄香烯口服乳+奥沙利铂+替吉奥	(pdbhnimkva) = gaknphatbb aczichpgtr (jozwcsvmcn ) View more	Positive	25 Sep 2021
				奥沙利铂+替吉奥	(pdbhnimkva) = ylmgxhdstw aczichpgtr (jozwcsvmcn ) View more
CSCO2021	Not Applicable	-	65	榄香烯注射液联合TMZ(替莫唑胺)	lpphotaxlx(bwdxeynisr) = dhhctiqkeh goritoxhqw (vcjbcdyfny )	Positive	25 Sep 2021
				单TMZ组	lpphotaxlx(bwdxeynisr) = vxofiwzugr goritoxhqw (vcjbcdyfny )
CSCO2021	Not Applicable	Liver Cancer	60	榄香烯注射液联合放疗	lcccjvbqtq(ajobpikhrv) = rdsrlanfpe manzjqfufw (byjvouglnm ) View more	Positive	25 Sep 2021
				榄香烯注射液 (单纯放疗)	lcccjvbqtq(ajobpikhrv) = asotquxclf manzjqfufw (byjvouglnm )
CSCO2020	Not Applicable	Non-Small Cell Lung Cancer \| Brain metastases	90	榄香烯注射液联合全脑放疗	qqjvnoejot(kxlyugqrgu) = gpyorwilie qedjdqlvgr (ksauwywyqr ) View more	-	19 Sep 2020
				榄香烯注射液 (全脑放疗)	qqjvnoejot(kxlyugqrgu) = jnlxbeloyo qedjdqlvgr (ksauwywyqr ) View more
CSCO2020	Not Applicable	Liver Cancer	60	榄香烯注射液联合介入化疗	xkfhwqerjk(icnnocttff) = 榄香烯组明显减轻，两组比较差异有统计学意义(P<0.05) zzedlizaca (ixzoqpkisv ) View more	-	19 Sep 2020
				榄香烯注射液 (介入化疗)
CSCO2020	Not Applicable	Hypopharyngeal Carcinoma	56	榄香烯口服乳	vtbywucfyk(zqoahzxtvm) = uvnqztomks tfedbeoghk (ckhxxivavp ) View more	Positive	19 Sep 2020
				同步放化疗	vtbywucfyk(zqoahzxtvm) = ilszoenpzc tfedbeoghk (ckhxxivavp ) View more
CSCO2020	Not Applicable	Malignant ascites	42	腹腔灌注榄香烯注射液	khohrpvnvr(hvhgpbfswn) = rrvyzbnkin ydfnfwtgkv (gejxcrmjtc )	Positive	19 Sep 2020
CSCO2020	Not Applicable	Advanced gastric carcinoma	50	榄香烯口服乳	(zghkqgfirx) = wmntdphqst baiddpbnun (mogcwhbwla ) View more	Positive	19 Sep 2020
				榄香烯 (最佳支持治疗)	(zghkqgfirx) = qyegnuotuy baiddpbnun (mogcwhbwla )